Abrégé

The present invention relates to a controlled release formulation comprising: Mirabegron or a pharmaceutically acceptable salt thereof; an isomalt; and a sustained release agent. Disclosed is a formulation in which Mirabegron, a medication, does not decompose, and thus the therapeutic effect thereof can be maintained constant during long-term storage. Moreover, Mirabegron can be released stably and sustainably in vivo, and thus a sufficient medicinal effect can be exhibited even when the formulation is administered once a day.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 31/426 - 1,3-Thiazoles

Abrégé

The present invention provides an apixaban pharmaceutical formulation for delayed release of drug, comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core, characterized in that a release lag time is from 5 to 360 minutes and 60% or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 10% by weight, as measured in 900 mL of dissolution medium at 37℃ using a USP Apparatus 2 at a rotation speed of 75 rpm; and a method for preparing the same.

Classes IPC  ?

• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present invention relates to a breast cancer diagnosis composition using multiple autobodies and a breast cancer diagnosis kit using same. When used as a breast cancer diagnosis marker, a recombinant protein relevant to a breast cancer-related autoantibody allows breast cancer to be diagnosed using a non-invasive biological sample, such as blood, plasma, or serum, alone, even without any biopsy. The combined use of recombinant proteins capable of detecting breast cancer-related autoantibodies brings about higher accuracy in the diagnosis of breast cancer than the individual use of the recombinant proteins and can be used for breast cancer diagnosis kit having excellent specificity over other carcinomas.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/81 - Inhibiteurs de protéase

Abrégé

Paeonia Suffruticosa Andrews including antibacterial activity, bone reinforcement, antiphlogistic activity, blood nourishment, vigoration, etc. may bring about a synergistic effect on the prevention, treatment and improvement of an inflammatory disease.

Classes IPC  ?

• A61K 36/24 - Apocynaceae (famille de l'Apocynum venetum), p. ex. plumeria ou pervenche
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
• A61K 9/20 - Pilules, pastilles ou comprimés
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, having a phytosterol compound or a pharmaceutically acceptable salt thereof as an active ingredient. Having therapeutic activity for inflammatory diseases, the phytosterol compound is also applicable to a quasi-drug composition, a health functional food composition, and a cosmetic composition, all of which are intended to prevent or improve inflammation. Also, a method is provided for treating an inflammatory disease by administering the pharmaceutical composition to a subject in need thereof. As a natural materials, the phytosterol compound can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines.

Classes IPC  ?

• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a novel compound, named 2-ethoxy-4-(3-hydroxy-2-oxopropyl) phenyl 2-oxoacetate or a pharmaceutically acceptable salt thereof, which shows anti-inflammatory activity, and a method for preparing the same. Also, a pharmaceutical composition for preventing or treating inflammatory diseases, having the compound or a pharmaceutically acceptable salt thereof as an active ingredient is disclosed. Having therapeutic activity for inflammatory diseases, the phenylester compound is also applicable to a quasi-drug composition, a health functional food composition, and a cosmetic composition, all of which are intended to prevent or improve inflammation. Also, a method is provided for treating an inflammatory disease by administering the pharmaceutical composition to a subject in need thereof. As a natural materials, the novel phenylester compound can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines.

Classes IPC  ?

• C07C 69/736 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a pharmaceutical composition for preventing and treating an inflammatory disease, including a mixture of extracts from Trachelospermi Caulis and Paeonia Suffruticosa Andrews as an active ingredient and method for preparing the same. Also, a quasi-drug composition, a health functional food composition and a cosmetic composition, all based on the mixture, are provided for preventing or improving inflammation. In addition, the present invention relates to a method for treating an inflammatory disease by administering the pharmaceutical composition to a subject suspected of having the inflammatory disease. Containing the extract mixture, the composition exhibits excellent anti-inflammatory activity and edema-suppressing activity, compared to individual extracts, and thus can be applied to the prevention, treatment or improvement of an inflammatory disease. As natural materials, the extracts can be used as a safe therapeutic relatively free of fungal infection or other side-effects, compared to synthetic medicines. In addition, the known physiological activities of the extracts from Trachelospermi Caulis and Paeonia Suffruticosa Andrews including antibacterial activity, bone reinforcement, antiphlogistic activity, blood nourishment, vigoration, etc. may bring about a synergistic effect on the prevention, treatment and improvement of an inflammatory disease.

Classes IPC  ?

• A61K 36/24 - Apocynaceae (famille de l'Apocynum venetum), p. ex. plumeria ou pervenche
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Pyrola japonica in a predetermined range thereby exhibiting superior on therapeutic effects for the treatment of pains, acute inflammation, secretion of enzymes associated with factors inducing inflammation, and production of NO, iNOS, etc., as compared to those prepared from single herbal drugs, thus being useful in the prevention and treatment of inflammatory diseases such as arthritis.

Classes IPC  ?

• A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes